Demyelination in Parkinson’s disease: Not just a secondary bystander, but also as an active contributor to pathogenesis
Advanced Neurology · 2026-05-15 · 5 (4) · 025510128
DOI: 10.36922/an025510128 ↗Abstract
Parkinson’s disease (PD) primarily affects the gray matter, with a gradual loss of dopaminergic neurons in the substantia nigra and the buildup of intraneuronal α-synuclein. Recent neuroimaging and neuropathological studies have indicated widespread alterations in white matter microstructure, raising a vital question: Is demyelination merely a consequence of axonal degeneration, or does it actively drive neurodegeneration? This review discusses the role of demyelination in PD and highlights future research directions. A literature search was conducted using keywords such as “myelin,”“demyelination,” “bystander,” “remyelination,” “impact of demyelination,” “causes of Parkinson’s,” Parkinson’s disease,” “myelination,” “functional magnetic resonance imaging,” “neurodegeneration,” “factors affecting Parkinson’s,” “PD,” “α-synuclein,” “synucleinopathy,” and “aging” across Scopus, Web of Science, OpenGrey, PubMed, ResearchGate, Cochrane Library, and Google Scholar. These terms were systematically combined using Boolean operators and linked to Parkinsonism. The review prioritized peer-reviewed studies published in the last 10 to 15 years to highlight recent findings, with a few older key studies included. The collected evidence presents a complex picture: the “bystander” hypothesis, which posits that neuronal death triggers Wallerian degeneration and myelin breakdown, is supported; however, multiple lines of evidence also suggest an early, active role for oligodendrocytes. α-synuclein buildup disrupts cellular metabolic support, leading to energy deficits in axons and heightened oxidative stress before neurons are visibly lost. Furthermore, neuroinflammatory responses associated with early demyelination exacerbate the toxic environment, accelerating dopaminergic neuron loss. In conclusion, demyelination is both a consequence and an active contributor to PD progression. Recognizing these dynamics offers new opportunities for therapies that protect myelin, potentially transforming the course of PD.
EUVIMED